Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

Read full text
Authors: Amaya López-Pascual, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya, Maria Ujue Latasa, Elizabeth Anaya, Elena Adán-Villaescusa, Borja Castelló-Uribe, Luz Andrea Martínez‐Pérez, Iker Uriarte, María Arechederra, Sergio Ciordia, Fernando José Corrales
+11 more Pavel Strnad, Soňa Fraňková, Eva Sticová, Ondřej Fabián, Leticia Colyn, Patrícia Inácio, Juan Bayo, Meritxell Huch, Carmen Berasain, Maite G. Fernández‐Barrena, Matias Antonio Avila
Cited by: 0
References: 128

Abstract

Abstract Background Epigenetic alterations play an increasingly recognized role in carcinogenesis and in the development of resistance to anticancer therapies. Epigenetic enzymes (writers and erasers) and effectors (readers) are largely influenced by the availability of metabolites grenerated through one-carbon metabolism (OCM), the tricarboxylic acid (TCA) cycle, and acetyl-CoA synthesis (ACS). In this study we examined the expression of epigenetic and metabolic genes to investigate their interplay in cholangiocarcinoma (CCA). Method We examined 257 epigenetic genes (EpiGs), 96 metabolic genes (MGs), and 189 rate-limiting enzymes (RLEs) in transcriptomic data from iCCA, eCCA, CCA organoids, and normal bile ducts, alongside prognostic signatures. CRISPR-Cas9 DepMap data evaluated the impact of EpiGs and MGs on cell viability. HuCCT-1 iCCA cells were exposed to hypoxia (1% O₂, 24 h) to assess EpiG responses. Transcriptomic deconvolution characterized EpiGs, MGs, and RLEs expression across four tumor microenvironment (TME) subtypes. Two mouse CCA models (Akt/TAZ, Akt/NICD) underwent RNA-seq, complemented by multi-omic profiling (transcriptomic, proteomic, metabolomic) in Akt/TAZ livers. Results Several EpiGs were upregulated in iCCA and eCCA, including writers ( DNMT1 , EZH2 , SUZ12 ), readers ( CBX3 , PHF20L1 , SMARCA4 ), and erasers ( HDAC1 , HDAC3 , KDM5C ). MGs in OCM, TCA, and ACS pathways were dysregulated (up: GART , IDH2 , TYMS ; down: ALDH1L1 , MAT1A , SHMT1 ). Integrated analyses identified 27 EpiGs and 8 MGs whose overexpression predicted poor survival. Subsets of EpiGs, MGs, and RLEs were linked to proliferative, high-recurrence iCCA subclasses. CRISPR screens highlighted 50 EpiGs and 23 MGs essential for CCA viability. Tumor microenvironment (TME) analyses revealed distinct immune-stromal subclasses with coherent epigenetic-metabolic signatures. In CCA cells, hypoxia induced epigenetic programs that mirrored those in CCA patients. Transcriptomic analyses in human and multi-omic analyses (transcriptomic, metabolomic, and proteomic studies) in mouse CCA livers highlighted rewiring of nucleotide, one-carbon, lipid, and mitochondrial pathways, with evidence of metabolic-epigenetic crosstalk. Conclusion EpiGs and MGs are markedly altered in both human and experimental CCA, with several changes particularly enriched in aggressive molecular subclasses associated with poor prognosis. We observed substantial rewiring of epigenetic cofactor-related MG expression in CCAs. Functional assays validated new targets among EpiGs (e.g. CBX3 , CHD4 , DEK , SMARCA4 , and TRIM28 ) and MGs ( TYMS and IDH2 ) in CCA.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Histone Deacetylase Inhibitors Research Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Frontiers in Cell and Developmental Biology
Publisher
Frontiers Media SA
Volume
14
Pages
1765945–1765945
Publication date
4 June 2026
Language
EN